These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
556 related articles for article (PubMed ID: 10197794)
1. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Stewart DA; Guo D; Morris D; Poon MC; Ruether BA; Jones AR; Klassen J; Auer I; Luider J; Chaudhry A; Brown C; Russell JA Bone Marrow Transplant; 1999 Jan; 23(2):111-7. PubMed ID: 10197794 [TBL] [Abstract][Full Text] [Related]
2. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF. Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898 [TBL] [Abstract][Full Text] [Related]
3. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284 [TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
5. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353 [TBL] [Abstract][Full Text] [Related]
6. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH; Schulman KA; Buckner CD Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [TBL] [Abstract][Full Text] [Related]
7. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Alegre A; Tomás JF; Martínez-Chamorro C; Gil-Fernández JJ; Fernández-Villalta MJ; Arranz R; Díaz MA; Granda A; Bernardo MR; Escudero A; López-Lorenzo JL; Fernández-Rañada JM Bone Marrow Transplant; 1997 Aug; 20(3):211-7. PubMed ID: 9257889 [TBL] [Abstract][Full Text] [Related]
8. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF. Gómez-Espuch J; Moraleda JM; Ortuño F; Lozano ML; Ayala F; Vallejo C; de Arriba F; Vicente V Bone Marrow Transplant; 2000 Feb; 25(3):231-5. PubMed ID: 10673692 [TBL] [Abstract][Full Text] [Related]
9. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Watts MJ; Ings SJ; Leverett D; MacMillan A; Devereux S; Goldstone AH; Linch DC Br J Cancer; 2000 Jan; 82(2):278-82. PubMed ID: 10646877 [TBL] [Abstract][Full Text] [Related]
11. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia. Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727 [TBL] [Abstract][Full Text] [Related]
12. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi Sai S; Teagarden D; Hamilton ES; Waller EK; Kaufman J Transfusion; 2007 Apr; 47(4):629-35. PubMed ID: 17381621 [TBL] [Abstract][Full Text] [Related]
13. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF]. Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058 [TBL] [Abstract][Full Text] [Related]
14. A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. Corso A; Arcaini L; Caberlon S; Zappasodi P; Mangiacavalli S; Lorenzi A; Rusconi C; Troletti D; Maiocchi MA; Pascutto C; Morra E; Lazzarino M Haematologica; 2002 Oct; 87(10):1041-5. PubMed ID: 12368158 [TBL] [Abstract][Full Text] [Related]
15. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688 [TBL] [Abstract][Full Text] [Related]
16. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg). Kröger N; Zeller W; Hassan HT; Krüger W; Gutensohn K; Löliger C; Zander AR Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796 [TBL] [Abstract][Full Text] [Related]
17. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation. Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420 [TBL] [Abstract][Full Text] [Related]
18. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor. Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727 [TBL] [Abstract][Full Text] [Related]
19. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563 [TBL] [Abstract][Full Text] [Related]
20. Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients. Kolbe K; Peschel C; Rupilius B; Després D; Burger K; Sklenar I; Färber L; Huber C; Derigs HG Bone Marrow Transplant; 1997 Dec; 20(12):1027-32. PubMed ID: 9466274 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]